Clinical trial
A Phase 2, Randomized, Multicenter, Active-controlled, Double-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a 2-dose Regimen of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 79 Years Old
NCT07205796 is registered in ClinicalTrials.gov with Shenzhen Shenxin Biotechnology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Multicenter, Active-controlled, Double-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a 2-dose Regimen of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants 50 to 79 Years Old
- Lead sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- May 1, 2026
- Completion date
- December 30, 2027
- Enrollment
- 480 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.